Dechra Pharmaceuticals plc

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP

G2769C145
SEDOL

0963318
CIK

N/A

dechra.com
LEI:
FIGI: BBG000JDPN39
DPH

Dechra Pharmaceuticals plc
GICS: 35202010 · Sector: Pet medicine · Sub-Sector: -
NAME
Dechra Pharmaceuticals plc
ISIN
GB0009633180
TICKER
DPH
MIC
XLON
REUTERS
DPH.L
BLOOMBERG
DPH LN
EN 728x90
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
In this section you will find transaction histories for short sales.
ai
NALIZER
Short sellers are obliged to report when building up positions from 0.50% and when reducing positions up to 0.50%. If there are open positions >= 0.50% in the reporting registers, these are shown in the following overview.
Two Short sale positions >= 0.50% are currently registered as reportable-relevant
Date Position Holder Position # Action
15.01.2024 Qube Research & Technologies Limited 0,53% 59
02.06.2023 AQR Capital Management, LLC 0,51% 1
The overview shows all positions and their last reported status. Please note that when reducing positions, falling below the 0.50% limit means that the mandatory reporting obligations no longer have to be applied. As a rule, it can be assumed that the positions have been completely reduced following a longer period of inactivity. Positions < 0.50% are therefore only of limited significance.
Date Position Holder Position # Action
15.01.2024 Qube Research & Technologies Limited 0,53% 59
02.06.2023 AQR Capital Management, LLC 0,51% 1
20.04.2023 WorldQuant LLC 0,49% 8
14.04.2023 GLG Partners LP 0,38% 2
14.04.2023 GLG Partners LP 0,38% 7
12.05.2020 SFM UK Management LLP 0,46% 4
19.03.2020 Polar Capital LLP 0,46% 2
06.01.2020 Jupiter Investment Management Limited 0,47% 2
22.05.2019 AHL Partners LLP 0,49% 6
15.03.2019 BlackRock Institutional Trust Company, National Association 0,47% 4
04.03.2019 Systematica Investments Limited 0,49% 2
23.01.2019 Numeric Investors LLC 0,11% 4
14.07.2016 BlackRock Investment Management (UK) Limited 0,48% 6
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements
The information provided in this area is compiled with care and prepared and processed in complex technical process steps. Quality assurance is an integral part of the methods and procedures used. A plausibility check is carried out to the extent that the source data allows. Before further use, especially in the course of any investment decisions, we recommend consulting at least one second independent source for validation.